Parcourir par auteur "Madersbacher, H."
Voici les éléments 1-4 de 4
-
Botulinum neurotoxin A for benign prostatic hyperplasia
Oeconomou, A.; Madersbacher, H. (2010)Purpose of review The injection of botulinum neurotoxin A (BoNT-A) into the prostate represents an alternative, minimal invasive treatment for lower urinary tract symptoms suggestive of benign prostatic hyperplasia (BPH), ... -
Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature
Oeconomou, A.; Madersbacher, H.; Kiss, G.; Berger, T. J.; Melekos, M.; Rehder, P. (2008)Context: The intraprostatic injection of botulinum neurotoxin type A (BoNT-A) is a minimally invasive but still-experimental treatment of lower urinary tract symptoms (LUTS) due to benign prostatic enlargment (BPE) based ... -
Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature Editorial Comment
Oeconomou, A.; Madersbacher, H.; Kiss, G.; Berger, T. J.; Melekos, M.; Rehder, P. (2009) -
Reply to Giuseppe Brisinda, Serafino Vanella and Giorgio Maria's Letter to the Editor re: Athanassios Oeconomou, Helmut Madersbacher, Gustav Kiss, Thomas J. Berger, Michael Melekos and Peter Rehder. Is Botulinum Neurotoxin Type A (BoNT-A) a Novel Therapy for Lower Urinary Tract Symptoms Due to Benign Prostatic Enlargement? A Review of the Literature. Eur Urol 2008;54:765-77
Oeconomou, A.; Melekos, M.; Madersbacher, H. (2009)